Fig. 6.

Exosomes mediate gCTRP9/CTRP9-281 enhancement of CBSC cardioprotection. A: Western blots and quantification protein expression utilizing adult mouse cardiomyocytes cell lysis. Cardiomyocytes were treated with exosomes isolated from gCTRP9 or CTRP9-281 treated CBSCs for 24h followed by H₂O₂ treatment for 2 h *P < 0.05, **P < 0.01. B-D: CBSC were pre-treated with neutral sphingomyelinase-2 (nSMase2) inhibitor GW4869 (2 μg/ml) before their intramyocardial injection. GW4869 attenuated the synergistic anti-fibrotic (B) and cardiac functional improvement (C/D) effect of CTRP9-281 and CBSC. n = 6–10/group, *P < 0.05.